The Heartmate Risk Score Predicts Morbidity and Mortality in Unselected Left Ventricular Assist Device Recipients and Risk Stratifies INTERMACS Class 1 Patients

JACC: Heart Failure

Volumn 3, Issue 4, 2015, Pages 283-290

  Adamo, Luigi ^a   Nassif, Michael ^a   Tibrewala, Anjan ^a   Novak, Eric ^a   Vader, Justin ^a   Silvestry, Scott C ^a   Itoh, Akinobu ^a   Ewald, Gregory A ^a   Mann, Douglas L ^a   LaRue, Shane J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AUC; GI; Heart failure; HMII; HMRS; INTERMACS; Left ventricular assist device; LVAD; ROC; Survival; Transplantation

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEARTMATE RISK SCORE; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CODING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; EVALUATION STUDY; HEART ASSIST DEVICE; HEART FAILURE; KAPLAN MEIER METHOD; MORTALITY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

COHORT STUDIES; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK ASSESSMENT; ROC CURVE; TREATMENT OUTCOME;

EID: 84926420377     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.11.005     Document Type: Article

References (15)

1. Miller L.W., Pagani F.D., Russell S.D., et al. Use of a continuous-flow device in patients awaiting heart transplantation. NEngl J Med 2007, 357:885-896.
2. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. NEngl J Med 2001, 345:1435-1443.
3. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Sixth INTERMACS annual report: a 10,000-patient database. JHeart Lung Transplant 2014, 33:555-564.
4. Long E.F., Swain G.W., Mangi A.A. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014, 7:470-478.
5. Levy W.C. Potential clinical applications of the HeartMate II risk score. JAm Coll Cardiol 2013, 61:322-324.
6. Boyle A.J., Ascheim D.D., Russo M.J., et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. JHeart Lung Transplant 2011, 30:402-407.
7. Cowger J., Sundareswaran K., Rogers J.G., et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. JAm Coll Cardiol 2013, 61:313-321.
8. Park S.J., Milano C.A., Tatooles A.J., et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012, 5:241-248.
9. Thomas S.S., Nahumi N., Han J., et al. Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: application of the HeartMate II risk score. JHeart Lung Transplant 2014, 33:675-681.
10. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. JBiomed Inform 2009, 42:377-381.
11. Uno H., Tian L., Cai T., Kohane I.S., Wei L.J. Aunified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 2013, 32:2430-2442.
12. Stevenson L.W., Pagani F.D., Young J.B., et al. INTERMACS profiles of advanced heart failure: the current picture. JHeart Lung Transplant 2009, 28:535-541.
13. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. JHeart Lung Transplant 2013, 32:141-156.
14. Kirklin J.K., Naftel D.C., Kormos R.L., et al. The fourth INTERMACS annual report: 4,000 implants and counting. JHeart Lung Transplant 2012, 31:117-126.
15. Uriel N., Pak S.W., Jorde U.P., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. JAm Coll Cardiol 2010, 56:1207-1213.